Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation.

The Journal of biological chemistry - 27 Apr 2012

Leonardi Roberta, Subramanian Chitra, Jackowski Suzanne, Rock Charles O

Abstract excerpt

Isocitrate dehydrogenase (IDH) is a reversible enzyme that catalyzes the NADP(+)-dependent oxidative decarboxylation of isocitrate (ICT) to α-ketoglutarate (αKG) and the NADPH/CO(2)-dependent reductive carboxylation of αKG to ICT. Reductive carboxylation by IDH1 was potently inhibited by NADP(+) and, to a lesser extent, by ICT. IDH1 and IDH2 with cancer-associated mutations at the active site arginines were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetyl Coenzyme A
Share to Cell Hypoxia
Share to Isocitrate Dehydrogenase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitochondria

Share to Mitochondrial Proteins

Share to Neoplasm Proteins

Share to Oxidation-Reduction

Source

Open in PubMed Open full text

Identifiers

PMID: 22442146
DOI: 10.1074/jbc.C112.353946
PMCID: PMC3340216

Genes

IDH1
IDH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation.PMID 22442146Read ↗

IDH mutations in tumorigenesis and their potential role as novel therapeutic targets.Semantic proximity Read ↗

Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.Semantic proximity Read ↗

Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors.Semantic proximity Read ↗

Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.Semantic proximity Read ↗

Isocitrate dehydrogenase mutations in myeloid malignancies.Semantic proximity Read ↗

Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates.Semantic proximity Read ↗

Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human diseaseSemantic proximity Read ↗

Mutant IDH1 enhances the production of 2-hydroxyglutarate due to its kinetic mechanism.Semantic proximity Read ↗

Evaluating Mechanisms of IDH1 Regulation through Site-Specific Acetylation Mimics.Semantic proximity Read ↗

Low pH Facilitates Heterodimerization of Mutant Isocitrate Dehydrogenase IDH1-R132H and Promotes Production of 2-Hydroxyglutarate.Semantic proximity Read ↗

A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of αHG.Semantic proximity Read ↗

Single arginine mutation in two yeast isocitrate dehydrogenases: biochemical characterization and functional implication.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.